严重创伤儿童中使用氨甲环酸的贝叶斯自适应临床试验设计
本研究设计了一项双盲、贝叶斯自适应临床试验,拟纳入最多2000例儿童头部和/或躯干出血性创伤患者,比较三种剂量氨甲环酸(15 mg/kg、30 mg/kg、45 mg/kg 单次推注)与安慰剂。该设计采用扩展的Emax剂量-反应模型并纳入层次结构,可在不同损伤人群(单纯头部损伤、单纯躯干损伤或头躯干联合损伤)中分别评估并确定最佳剂量。
要点
- 该试验为双盲、贝叶斯自适应设计,拟纳入最多2000例儿童出血性创伤患者。
- 比较氨甲环酸15 mg/kg、30 mg/kg、45 mg/kg单次推注剂量与安慰剂。
- 按损伤人群分层(单纯头部、单纯躯干、头躯干联合),可分别确定最佳剂量。
核心结论
- 该试验设计可在单一研究框架内分析并比较三种不同损伤人群,并分别得出各损伤组氨甲环酸最佳剂量的结论。
研究设计与样本
- 双盲、贝叶斯自适应临床试验,拟纳入最多2000例儿童头部和/或躯干出血性创伤患者。
- 扩展传统Emax剂量-反应模型并纳入层次结构,以在不同损伤人群中评估多个氨甲环酸剂量。
- 比较最多3种氨甲环酸剂量(15 mg/kg、30 mg/kg、45 mg/kg 单次推注)与安慰剂。
- 在每个损伤组初始阶段,安慰剂、15 mg/kg和30 mg/kg之间采用等比例分配。
- 根据剂量-反应曲线,若基于低剂量数据观察到疗效增加趋势,45 mg/kg组可在该损伤组开放。
主要发现
- 反应自适应随机化允许各损伤组的氨甲环酸分配比例不同,从而为每个损伤组确定最佳剂量。
- 纳入频繁的中期停止期以评估疗效和无效性。
- 通过广泛模拟评估统计设计在多种合理情景下的操作特征。
- 该试验在每个损伤组均达到足够的检验效能。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trauma is the leading cause of death and disability in children in the USA. Tranexamic acid (TXA) reduces the blood transfusion requirements in adults and children during surgery. Several studies have evaluated TXA in adults with hemorrhagic trauma, but no randomized controlled trials have occurred in children with trauma. We propose a Bayesian adaptive clinical trial to investigate TXA in children with brain and/or torso hemorrhagic trauma. METHODS/DESIGN: We designed a double-blind, Bayesian adaptive clinical trial that will enroll up to 2000 patients. We extend the traditional Emax dose-response model to incorporate a hierarchical structure so multiple doses of TXA can be evaluated in different injury populations (isolated head injury, isolated torso injury, or both head and torso injury). Up to 3 doses of TXA (15 mg/kg, 30 mg/kg, and 45 mg/kg bolus doses) will be compared to placebo. Equal allocation between placebo, 15 mg/kg, and 30 mg/kg will be used for an initial period within each injury group. Depending on the dose-response curve, the 45 mg/kg arm may open in an injury group if there is a trend towards increasing efficacy based on the observed relationship using the data from the lower doses. Response-adaptive randomization allows each injury group to differ in allocation proportions of TXA so an optimal dose can be identified for each injury group. Frequent interim stopping periods are included to evaluate efficacy and futility. The statistical design is evaluated through extensive simulations to determine the operating characteristics in several plausible scenarios. This trial achieves adequate power in each injury group. DISCUSSION: This trial design evaluating TXA in pediatric hemorrhagic trauma allows for three separate injury populations to be analyzed and compared within a single study framework. Individual conclusions regarding optimal dosing of TXA can be made within each injury group. Identifying the optimal dose of TXA, if any, for various injury types in childhood may reduce death and disability.
引用
- VanBuren JM, Casper TC, Nishijima DK, et al. The design of a Bayesian adaptive clinical trial of tranexamic acid in severely injured children. Trials. 2021. PMID: 34736498. doi:10.1186/s13063-021-05737-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。